512,641 Shares in Fate Therapeutics, Inc. (NASDAQ:FATE) Acquired by Marshall Wace LLP

Marshall Wace LLP bought a new stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 512,641 shares of the biopharmaceutical company's stock, valued at approximately $846,000. Marshall Wace LLP owned 0.45% of Fate Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Geode Capital Management LLC boosted its position in Fate Therapeutics by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company's stock valued at $7,905,000 after buying an additional 10,863 shares during the period. JPMorgan Chase & Co. increased its stake in Fate Therapeutics by 18.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company's stock valued at $6,431,000 after purchasing an additional 283,080 shares in the last quarter. Walleye Capital LLC lifted its position in Fate Therapeutics by 1,502.0% in the 4th quarter. Walleye Capital LLC now owns 1,083,092 shares of the biopharmaceutical company's stock valued at $1,787,000 after acquiring an additional 1,015,483 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of Fate Therapeutics by 4,953.6% during the fourth quarter. Cerity Partners LLC now owns 823,134 shares of the biopharmaceutical company's stock valued at $1,358,000 after purchasing an additional 806,846 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Fate Therapeutics by 245.3% during the third quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company's stock valued at $1,485,000 after buying an additional 301,389 shares during the last quarter. 97.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

FATE has been the topic of several research analyst reports. StockNews.com cut shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday, March 11th. Wedbush reissued a "neutral" rating and set a $5.00 price target on shares of Fate Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company cut their price objective on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a report on Thursday, March 6th. Finally, Stifel Nicolaus lowered their price objective on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Fate Therapeutics currently has a consensus rating of "Hold" and an average price target of $5.43.

Fate Therapeutics Price Performance

FATE stock traded down $0.06 during trading on Tuesday, hitting $1.12. 506,426 shares of the company traded hands, compared to its average volume of 2,276,056. Fate Therapeutics, Inc. has a 1 year low of $0.66 and a 1 year high of $5.92. The stock's 50-day simple moving average is $1.01 and its 200 day simple moving average is $1.61. The company has a market cap of $127.78 million, a PE ratio of -0.68 and a beta of 2.31.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. The company had revenue of $1.86 million during the quarter, compared to analysts' expectations of $1.57 million. Research analysts expect that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.